Print Friendly, PDF & Email

Global Fund secures deal to slash HIV treatment price

Facts for Prelims (FFP)

Source: TH

 Context: The Global Fund, has reached an agreement with generic pharmaceutical manufacturers to significantly reduce the price of an advanced HIV drug named TLD.

  • This deal will allow the drug to be provided for under $45 per person per year, marking a 25% reduction in cost.
  • The TLD pill contains three essential drugs for HIV treatment: tenofovir disoproxil fumarate, lamivudine, and dolutegravir.

This combination has been recommended by the World Health Organization as the preferred first-line treatment for HIV in adults and adolescents due to its effectiveness in suppressing the virus, minimal side effects, and ease of use.

 

About Global Fund: 

The Global Fund was established in 2002 to raise and disburse funding for programs that reduce the impact of HIV/AIDS, tuberculosis, and malaria in low- and middle-income countries. The Global Fund raises and invests $4 billion a year to fight these diseases. The majority of the Global Fund’s financial support comes from public resources. More than 80 countries have made or pledged contributions to the Global Fund.